CBD, or cannabidiol, is the most abundant cannabinoid in hemp and the second most abundant cannabinoid in cannabis. CBD is non-psychoactive and, according to the World Health Organization, “In humans, CBD exhibits no effects indicative of any abuse or dependence potential…. To date, there is no evidence of public health-related problems associated with the use of pure CBD.”

In December 2015, the FDA eased the regulatory requirements for FDA-approved clinical trials on cannabidiol, allowing researchers to register with the DEA to conduct CBD-based clinical trials. In December of 2018, the 2018 Farm Bill removed hemp (Cannabis sativa L.) and derivatives of cannabis with low concentrations of the THC (the psychoactive compound) of no more than 0.3 percent dry weight from the Controlled Substances Act (CSA). This bill granted the production and sale of hemp products abiding by FDA standard requirements alongside food, dietary supplements, veterinary drugs, and cosmetics.

There is currently a major concern over the lack of FDA regulations on hemp products. Other than the THC potency requirements, there are little to no regulations regarding the safety of hemp and hemp products. Consumers are concerned about quality and are purchasing products that have undergone assessments for potentially harmful contaminants.